Management of community-acquired acute bacterial cystitis in Turkey;Türkiye'de toplum kökenli akut baktriyel sistit tedavisi

Turkish Journal of Medical Sciences

Volumn 41, Issue 1, 2011, Pages 149-157

  Coşkun, Ömer ^a   Erdem, Hakan ^b   Avci, Ali ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

Community acquired; Infection; Turkey; Urinary

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED ACUTE BACTERIAL CYSTITIS; CONTROLLED STUDY; DRUG INDICATION; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; NONHUMAN; PROTEUS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TURKEY (REPUBLIC);

EID: 83155175492     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0908-158     Document Type: Article

References (70)

1. Wilson WR, Henry NK. Urinary tract infectious. In: Wilson WR SM, ed. Current diagnosis and treatment in infectious diseases USA: McGraw- Hill: İstanbul: Nobel Ti{dotless}p Kitabevi 2000: 220-30.
2. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999; 29: 745-58.
3. Türkiye Istatistik Kurumu. http://www.tuik.gov.tr/VeriBilgi.do?tb_id=6&ust_id=1. (in Turkish).
4. Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol, 2006; 24: 208-11.
5. Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am, 2003; 17: 303-32.
6. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother, 2003; 52: 1005-10.
7. Bean DC, Krahe D, Wareham DW. Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006. Ann Clin Microbiol Antimicrob, 2008; 7: 13.
8. Andreu A, Planells I. Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study. Med Clin (Barc), 2008; 130: 481-6.
9. Gupta K, Hooton TM, Stamm WE Increasing antimicrobial resistance and the management of uncomplicated communityacquired urinary tract infections. Ann Intern Med. 2001; 135: 41-50.
10. Alam MF, Cohen D, Butler C, Dunstan F, Roberts Z, Hillier S et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents, 2008; 15:(Epub ahead of print).
11. Sobel JD, Kaye D. Urinary Tract Infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6 ed: Churchill Livingstone 2005: 875-904.
12. McCarty JM, Richard G, Huck W, Tucker RM, Tosiello RL, Shan M et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. The American Journal of Medicine, 1999; 106: 292-9.
13. Nicolle L, Anderson PA, Conly J, Mainprize TC, Meuser J, Nickel JC et al. Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. Can Fam Physicia,. 2006; 52: 612-8.
14. McQuilkin M, Lund A, Palmer W. Antimicrobial resistance of uncomplicated urinary tract infections in northern Utah. Clin Lab Sci, 2008; 21: 99-101.
15. Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med, 2002; 113: 45-54.
16. Biswas D, Gupta P, Prasad R, Singh V, Arya M, Kumar A. Choice of antibiotic for empirical therapy of acute cystitis in a setting of high antimicrobial resistance. Indian J Med Sci, 2006; 60: 53-8.
17. Goldstein FW. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre Study Group. Eur J Clin Microbiol Infect Dis, 2000; 19: 112-7.
18. Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res, 2004; 120: 553-56.
19. Amsden GW. Tables of antimicroal agent pharmacology. In: Mandel GL BJDR, ed. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2000: 551-603.
20. Gagliotti C, Buttazzi R, Sforza S, Moro ML. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli, J Infect. 2008; 57: 179-84.
21. Baykan M, Kaya M, Arslan U, Baysal B. Idrar örneklerinden izole edilen E.coli suşlari{dotless}ni{dotless}n antimikrobiyallere duyarli{dotless}li{dotless}klari{dotless}ni{dotless}n deǧerlendirilmesi (The evaluation of antibiotic susceptibility patterns of E.coli strains isolated from urine specimens). Inönü Üniv Ti{dotless}p Fak Derg, 2001; 8: 15-7. (in Turkish).
22. Taşbakan MI, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Toplum kökenli üriner sistem infeksiyonlari{dotless}ndan soyutlanan Escherichi{dotless}a coli suşlari{dotless}na fosfomisinin in-vitro etkinliǧinin diǧer antibiyotiklerle karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless} (The comparison of fosfomycin with other antimicrobials in Escherichia coli strains isolated from community acquired UTIs). ANKEM Derg, 2004; 18: 216-19. (in Turkish).
23. Rafal'skii VV, Rokhlikov IM, Strachunskii LS. Clinicomicrobiological characteristics of community-acquired infections of the urinary tracts in Moscow. Urologia, 2007; 18: 20-3.
24. Gobernado M, Valdes L, Alos JI, Garcia-Rey C, Dal-Re R, Garcia-de-Lomas J. Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related differences. Rev Esp Quimioter, 2007; 20: 206-10.
25. Hima-Lerible H, Menard D, Talarmin A. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic. J Antimicrob Chemother, 2003; 51: 192-4.
26. Randrianirina F, Soares JL, Carod JF, Ratsima E, Thonnier V, Combe P, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother, 2007; 59: 309-12.
27. Fu Y, Zhang F, Zhang W, Chen X, Zhao Y, Ma J et al. Differential expression of bla(SHV) related to susceptibility to ampicillin in Klebsiella pneumoniae. International journal of antimicrobial agents, 2007; 29: 344-7.
28. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol, 2007; 7: 459-69.
29. Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtas M, Gurcuoglu E et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother, 2008; 20: 581-5.
30. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP et al. Community infections caused by extendedspectrum beta-lactamase-producing Escherichia coli. Arch Intern Med, 2008; 168: 1897-902.
31. Gupta K, Stamm WE. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. International journal of antimicrobial agents, 2002; 19: 554-6.
32. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother, 2007; 60: 247-57.
33. eckentdorf HK, Castringius RG, Spingler HK. Comparative pharmacodynamics, urinary excretion, and half-life determinations of nitrofurantoin sodium. Antimicrob Agents Chemother, 1962; 2: 531-37.
34. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA, 1995; 273: 41-5.
35. Fekete T. 5 days of nitrofurantoin was equivalent to 3 days of trimethoprim-sulfamethoxazole for women with noncomplicated cystitis. Evid Based Med, 2008; 13: 80.
36. Knottnerus BJ, Nys S, Ter Riet G, Donker G, Geerlings SE, Stobberingh E. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother, 2008; 62: 356-9.
37. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs, 1997; 53: 637-56.
38. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents, 2007; 29: 62-5.
39. Bozkurt ÖF, Kara C, Akarsu S, Çaǧlar M, Ünsal A. Semptomatik idrar yolu enfeksiyonu olan kadinlarin tedavisinde tek doz fosfomisin etkinliǧinin siprofloksasin ile karşilaştirilmasi{dotless} (The comparison of ciprofloxacin and single dose fosfomycin in the management of symptomatic urinary tract infections in women). Türk Urol Derg, 2008; 34: 360-62. (in Turkish).
40. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am, 1997; 11: 551-81.
41. Altoparlak Ü, Özek A, Aktaş F. Üriner sistem infeksiyonlari{dotless}ndan izole edilen bakterilerin çeşitli antibiyotiklere duyarli{dotless}li{dotless}klari{dotless} (The antibiotic susceptibility patterns of bacteria isolated from urinary tract infections). Türk Mikrobiyol Cem Derg, 2001; 32: 167-73. (in Turkish).
42. Timurkaynak F, Inci KE, Arslan H. Toplum kökenli ve nozokomiyal üriner sistem infeksiyonlari{dotless}ndan izole edilen etkenlerin daǧi{dotless}li{dotless}mi{dotless} ve antibiyotik duyarli{dotless}li{dotless}ǧi{dotless} (The distribution of agents and their antibiotic susceptibilities in community acquired and nosocomial UTIs). Ankara Üniv Ti{dotless}p Fak Mec, 2001; 54: 287-92. (in Turkish).
43. Savaş L, Güvel S, Turunç T, Savaş N, Arslan H. Toplum kökenli ve nazokomiyal üriner sistem enfeksiyon etkenleri ve antibiyotik duyarli{dotless}li{dotless}klari{dotless}ni{dotless}n karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless} (The causative agents isolated from community acquired and nosocomial UTIs and comparison of their antibiotic susceptibilities). Türk Üroloji Dergisi, 2003;29: 95-100. (in Turkish).
44. Arslan H, Azap ÖK, Ergönül Ö, Timurkaynak F Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. Journal of Antimicrobial Chemotherapy, 2005; 56: 914-18.
45. Akay H, Durunay M, Akay A. Üriner sistem enfeksiyonlari{dotless}ndan izole edilen mikroorganizmalari{dotless}n daǧi{dotless}li{dotless}mi{dotless} ve Escherichia coli suşlari{dotless}nda antibiyotik duyarli{dotless}li{dotless}ǧi{dotless} (The distribution and susceptibility patterns of microorganisms isolated from urinary tract infections). J Ist Faculty Med, 2006; 69: 1-4. (in Turkish).
46. Çetin M, Ocak S, Görür S, Avunduk G. Semtomatik üriner sistem enfeksiyonlari{dotless}nda üropatojenler ve izole edilen Escherichia coli suşlari{dotless}ni{dotless}n antibiyotik duyarli{dotless}li{dotless}ǧi{dotless} (The uropathogens in symptomatic UTIs and the antibiotic susceptibility of the Escherichia coli strains). ANKEM Derg, 2006; 20: 169-72. (in Turkish).
47. Pullukçu H, Taşbakan MI, Aydemir Ş, Sipahi OR, Turhan A, Özinel MA, Ulusoy S. İdrar kültürlerinde soyutlanan bakteriler ve çeşitli antibiyotiklere invitro duyarli{dotless}li{dotless}klari{dotless}ni{dotless}n deǧerlendirilmesi (The bacteria isolated from urine cultures and investigation of their susceptibilities to various antibiotics). ANKEM Derg, 2006; 20: 26-30.
48. Akan ÖA. İbn-i Sina hastanesinde poliklinik idrar örneklerinden izole edilen Escheri{dotless}chi{dotless}a coli izolatlari{dotless}ni{dotless}n ilk seçenek antibiyotiklere direnç durumu (The resistance of E.coli strains isolated from outpatients in Ibn-i Sina Hospital). Ankara Üniv Ti{dotless}p Fak Mecm, 2003; 56: 147-50. (in Turkish).
49. Dündar D, Topçu AW, Tamer GS. İdrar yolu infeksiyonu etkenleri ve antimikrobiyal duyarliliklari (The agents of UTIs and their antibiotic susceptibilities). Klimik Dergisi, 2008; 21: 7-11 (in Turkish).
50. Ay S, Işeri LA, Duman B. İdrar örneklerinden izole edilen gram olumsuz mikroorganizmalari{dotless}n antibiyotiklere duyarli{dotless}li{dotless}klari{dotless} (The antibiotic susceptibility of gram-negatives isolated from urine specimens). İnönü Üniversitesi Ti{dotless}p Fakültesi Dergisi, 2003; 10: 59-62. (in Turkish).
51. Sümer Z, Coşkunkan F, Vahapoǧlu H, Bakir M. The resistance of Escherichia coli strains isolated from community-acquired urinary tract infections. Advances in Therapy, 2005; 22: 419-23.
52. Yuluǧkural Z, Mutlu B. İdrar kültürlerinden izole edilen Escherichia coli suşlari{dotless}ni{dotless}n si{dotless}k kullani{dotless}lan antibakteriyellere karşi{dotless} duyarli{dotless}li{dotless}klari{dotless} (The susceptibilities of Escherichia coli strains isolated from UTIs to commonly used antibiotics). Trakya Univ Ti{dotless}p Fak Derg, 2007; 24: 6-11. (in Turkish).
53. Erdem H, Kilic S, Pahsa A, Besirbellioglu BA. Gram negative bacterial resistance to gram negative bacteria for cephalosporins in community acquired infections in Turkey. J Chemother, 2005; 17: 61-5.
54. Akçam ZF, Kaya O, Gönen İ, Yayli G. İdrar Örneklerinden Izole Edilen Toplum ve Hastane Kaynakli{dotless} Escherichia coli suşlari{dotless}nda Antibiyotik Direnci (The antibiotic resistance of Escherichia coli strains isolated from nosocomial and community acquired infections). OMU Ti{dotless}p Dergisi, 2004; 21: 23-7. (in Turkish).
55. Erdem H, Avci A, Pahsa A. Toplum kaynakli{dotless} üropatojenik Escherichia coli suşlari{dotless}nda antibakteriyel direnç (The antibiotic resistance in community acquired uropathogenic Escherichia coli strains). ANKEM Derg, 2004; 18: 40-4. (in Turkish).
56. Karaca Y, Coplu N, Gozalan A, Oncul O, Citil BE, Esen B Cotrimoxazole and quinolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years. Int J Antimicrob Agents, 2005; 26: 75-7.
57. Eroǧlu M, Koçoǧlu E, Karabay O, Semerciöz A. Toplum kaynakli{dotless} erişkin üriner sistem enfeksiyonlari{dotless}ndan izole edilen Enterobacteriacea türlerinin bazi{dotless} antibiyotiklere duyarli{dotless}li{dotless}klari{dotless} (The susceptibility of Enterobacteriacea species isolated from community acquired adult UTIs to various antibiotics). Türk Üroloji Dergisi, 2007; 33: 100-3. (in Turkish).
58. Ertuǧrul MB, Çolak N İdrardan izole edilen toplum kökenli Escherichia coli suşlari{dotless}ni{dotless}n antibiyotik duyarli{dotless}li{dotless}klari{dotless} (The antibiotic susceptibilities of community-acquired urinary E. coli isolates). ANKEM Derg, 2004;18: 161-5. (in Turkish).
59. Ertuǧrul MB, Güleç LA, Akal D, Çaǧatay AA, Özsüt H, Eraksoy H. Üropatojen Escherichia coli suşlari{dotless}ni{dotless}n tedavide si{dotless}k kullani{dotless}lan antibiyotiklere duyarli{dotless}li{dotless}klari{dotless} (The susceptibilities of uropathogenic E. coli strains to frequently used antibiotics). Klimik Derg. 2004; 17: 132-6. (in Turkish).
60. Kurutepe S, Surucuoglu S, Sezgin C, Gazi H, Gulay M, Ozbakkaloglu B. Increasing antimicrobial resistance in Escherichia coli isolates from community-acquired urinary tract infections during 1998-2003 in Manisa, Turkey. Jpn J Infect Dis, 2005; 58: 159-6.
61. Sucu N, Boz GA, Bayraktar Ö, Çaylan R, Aydin K, Köksal İ. Üropatojen Escherichia coli suşlari{dotless}ni{dotless}n antibiyotik duyarli{dotless}li{dotless}klari{dotless}ni{dotless}n yi{dotless}llar içerisindeki deǧişimi (The changes in antibiotic susceptibilities in uropathogen Escherichia coli strains). Klimik Derg. 2004; 17: 128-31. (in Turkish).
62. Şencan İ, Sevinç ME. Toplum Kökenli Üropatojen Escherichia coli izolatlari{dotless}nda antimikrobiyal direncin izlemi (The follow up of antibiotic resistance in community acquired Escherichia coli isolates). Klimik Derg, 2002; 15: 85-8. (in Turkish).
63. Bayraktar B, Özcan N, Borahan S, Başari F, Bulut E. Yatan ve ayaktan hastalardan izole edilen üriner sistem enfeksiyonu etkeni gram negatif çomaklarda antibiyotiklere direnç (The antibiotic resistance of gram negatives obtained from urinary tract infections in inpatients and outpatients). ANKEM Derg, 2004; 18: 137-40. (in Turkish).
64. Otaǧ F, Yildiz Ç, Delialioǧlu N. İdrardan soyutlanan Escherichia coli suşlari{dotless}nda antibiyotik direnci (The antibiotic resistance in Escherichia coli strains isolated from urine). ANKEM Derg, 2003; 17: 284-7. (in Turkish).
65. Ozyurt M, Haznedaroglu T, Sahiner F, Oncul O, Ceylan S, Ardic N et al. Antimicrobial resistance profiles of communityacquired uropathogenic Escherichia coli isolates during 2004-2006 in a training hospital in İstanbul. Mikrobiyol Bul. 2008; 42: 231-43.
66. KÖken G, Aşik G, Çifçi IH, Çetinkaya Z, Aktepe OC, Yilmazer M. Toplum kökenli üriner sistem infeksiyonu etkeni E.coli suşlari{dotless}nda fosfomisin trometamol etkinliǧi (The efficacy of fosfomycin trometamol in community acquired E.coli strains. ANKEM Derg, 2008; 22: 23-7. (in Turkish).
67. Afşar İ, Gönül B, Şener AG, Türker M. In-vitro susceptibility of clinical isolates of Escherichia coli to fosfamycin trometamol and other antibiotics. ANKEM Derg. 2005; 19: 77-9. (in Turkish).
68. Okaygün E, Kipritçi Ö, Akman A, Aydin D. Toplum ve hastane kaynakli{dotless} üriner sistem enfeksiyonlari{dotless}nda etken mikroorganizmalar ve antibiyotik direnci (The causative pathogens and their antibiotic susceptibilities in community acquired and nosocomial UTIs). ANKEM kongresi Antalya, 2006. (in Turkish).
69. Koçoǧlu E, Karabay O, Ince NK, Özkardeş F, Yildirim R. Toplum kaynakli{dotless} üriner sistem enfeksiyonlari{dotless}ndan izole edilen E. coli izolatlari{dotless}ndan genişletilmiş spektrumlu beta laktamaz ve bazi{dotless} antibiyotiklere direnç si{dotless}kli{dotless}ǧi{dotless}ni{dotless}n araşti{dotless}ri{dotless}lmasi{dotless} (The investigation of ESBL production and resistance profiles to various antibiotics in E.coli strains isolated form community acquired UTIs). ANKEM Derg, 2007; 21: 5-9. (in Turkish).
70. Bayraktar B, Özcan N, Borahan S, Başari F, Bulut E. Yatan ve ayaktan hastalardan izole edilen üriner sistem enfeksiyonu etkeni gram negatif çomaklarda antibiyotiklere direnç. ANKEM Derg, 2004; 18: 137-40.